Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.32 |
| ▸ | FADS1 | O60427 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843409 | 0.86 | CNR1 (0.36) | CNR1CRHR1FADS1CNR2DPP4 | |
| SCHEMBL3838038 | 0.82 | CNR1 (0.39) | CNR1CRHR1CNR2 | |
| SCHEMBL3838468 | 0.82 | CRHR1 (0.36) | CNR1CRHR1CNR2 | |
| SCHEMBL3840875 | 0.81 | CNR1 (0.41) | CNR1CNR2 | |
| SCHEMBL3840873 | 0.81 | CNR1 (0.41) | CNR1CNR2 | |
| SCHEMBL3842406 | 0.79 | CRHR1 (0.35) | CNR1CRHR1CNR2DPP4CYP3A4 | |
| SCHEMBL3838876 | 0.78 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL3841833 | 0.74 | CNR1 (0.39) | CNR1CRHR1CNR2CYP3A4 | |
| SCHEMBL6641175 | 0.74 | CRHR1 (0.39) | CNR1CRHR1CNR2CYP3A4 | |
| SCHEMBL3845074 | 0.74 | CRHR1 (0.39) | CNR1CRHR1CNR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446387-B1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | CNR1 66/4885CRHR1 27/4885FADS1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.